Michael Morris

Michael Morris was a principal investigator of the landmark VISION trial, the phase 3 randomized study that demonstrated Lu-177 PSMA-617 combined with standard of care significantly improves overall survival compared to standard of care alone in PSMA-positive metastatic castration-resistant prostate cancer, leading to FDA approval of Pluvicto. He has been instrumental in establishing PSMA PET imaging as the companion diagnostic for patient selection in radioligand therapy, validating the theranostic paradigm where the imaging agent predicts therapeutic benefit. His ongoing clinical trials are evaluating Lu-177 PSMA-617 in earlier disease settings and in combination with novel agents. His work has defined response assessment criteria for radioligand therapy in prostate cancer.